BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Radiology (1992) 65, 112-118
© 1992 British Institute of Radiology
doi: 10.1259/0007-1285-65-770-112
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wraight, E. P.
Right arrow Articles by Page-Thomas, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wraight, E. P.
Right arrow Articles by Page-Thomas, D. P.

The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma

E. P. Wraight, FRCR, PhD D. R. Bard, MSc, PhD {dagger} T. S. Maughan, FRCR, FRCP * C. G. Knight, PhD {dagger} and D. P. Page-Thomas, MB, BS, FRCPath {dagger}

Department of Nuclear Medicine, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ {dagger} University Department of Oncology and Radiotherapeutics, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ * Strangeways Research Laboratory, Worts' Causeway, Cambridge CB1 4RN, UK

A novel chelating derivative of alpha melanocyte stimulating hormone, bisMSH-DTPA, has been used for the diagnostic targeting of malignant melanoma. 15 patients were investigated of whom nine were shown by other means to have active disease at the time of the scan. Tumours were imaged in all of these nine patients. Of a total of 46 lesions over 10 mm encountered, 41 (89%) were imaged. There were no false positives and in two cases bisMSH-DTPA was instrumental in reversing diagnoses made using ultrasound. Derivatives of melanocyte stimulating hormone may be of considerable value in targeting melanomas.

Key Words: Melanoma • Alpha melanocyte stimulating hormone • Clinical study • Targeting • Diagnostic imaging • Indium 111

Received for publication March 14, 1991. Revision received July 23, 1991. Accepted for publication August 6, 1991.




This article has been cited by other articles:


Home page
 JNMHome page
Y. Miao, N. K. Owen, D. R. Fisher, T. J. Hoffman, and T. P. Quinn
Therapeutic Efficacy of a 188Re-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptide Analog in Murine and Human Melanoma-Bearing Mouse Models
J. Nucl. Med., January 1, 2005; 46(1): 121 - 129.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. R. Maecke, M. Hofmann, and U. Haberkorn
68Ga-Labeled Peptides in Tumor Imaging
J. Nucl. Med., January 1, 2005; 46(1_suppl): 172S - 178S.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. C. Reubi
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Endocr. Rev., August 1, 2003; 24(4): 389 - 427.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Chen, Z. Cheng, N. K. Owen, T. J. Hoffman, Y. Miao, S. S. Jurisson, and T. P. Quinn
Evaluation of an 111In-DOTA-Rhenium Cyclized {alpha}-MSH Analog: A Novel Cyclic-Peptide Analog with Improved Tumor-Targeting Properties
J. Nucl. Med., December 1, 2001; 42(12): 1847 - 1855.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Chen, Z. Cheng, T. J. Hoffman, S. S. Jurisson, and T. P. Quinn
Melanoma-targeting Properties of 99mTechnetium-labeled Cyclic {{alpha}}-Melanocyte-stimulating Hormone Peptide Analogues
Cancer Res., October 1, 2000; 60(20): 5649 - 5658.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. F. Giblin, N. Wang, T. J. Hoffman, S. S. Jurisson, and T. P. Quinn
Design and characterization of alpha -melanotropin peptide analogs cyclized through rhenium and technetium metal coordination
PNAS, October 27, 1998; 95(22): 12814 - 12818.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 1992 by the British Institute of Radiology.